Related Experiment Video
Updated: Jan 21, 2026
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
Published on: December 14, 2014
Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in
Tomoyuki Wada1, Kazunori Omatsu1, Stephen C Pflugfelder2
1From the Research and Development Division, Senju Pharmaceutical Co., Ltd. (T.W., K.O.), Osaka, Japan.
Purpose:
To investigate the safety, tolerability, pharmacokinetic profile, and efficacy of SJP-0132 in participants with dry eye disease (DED).
Design:
Phase 1/2, randomized, double-masked, single-center, placebo-controlled single and multiple ascending dose study.
Participants:
Generally healthy adults aged ≥18 years with a patient-reported history of DED for ≥6 months, eye dryness visual analog scale (VAS: 0-100) ≥40 mm, 5-item dry eye questionnaire (DEQ-5) ≥6, and central corneal fluorescein staining (CFS) of 2 to 4 (Baylor scale: 0-5 for each of five zones).
Methods:
This study consisted of Part A and Part B, containing four single- and two multiple-ascending dose cohorts, respectively. Following a 14-day placebo run-in, participants were randomized 1:3 to receive a single dose of placebo or SJP-0132 in each cohort in Part A. In Part B, participants were randomized 1:2 to receive placebo or SJP-0132 four times daily for 4 weeks in each cohort.
Main Outcome Measures:
The primary outcomes were the number and severity of adverse events, plasma concentration, and mean change from baseline in eye dryness VAS at 4 hours on Day 29 and in CFS score at the central zone on Day 29. Secondary end points included total CFS of all 5 zones, conjunctival staining, tear film break-up time, additional dry eye symptom VAS, DEQ-5, and tear matrix metalloproteinase-9.
Results:
Twenty-nine and 60 participants were randomized to Part A and B, respectively. Two of 21 and 6 of 40 participants who received SJP-0132 in each part reported at least one treatment-emergent adverse event (TEAE), compared with 0 of 8 and 7 of 20 for placebo. All TEAEs were mild. Plasma concentrations increased dose dependently. Eye dryness VAS decreased as early as 30 minutes after the first dose in the 0.1% and 0.3% groups in Part A and in the 0.3% group in Part B. The decrease persisted throughout the treatment period, although it was not statistically significant versus placebo. CFS scores decreased throughout the treatment period with a dose dependence similar to VAS.
Conclusions:
SJP-0132 was safe and well tolerated, plasma concentrations increased dose dependently, and efficacy data indicated that it improved both signs and symptoms of DED with a rapid onset of improvement.
More Related Videos
07:20Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
06:29Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Related Concept Videos
01:54The Placebo Effect
01:22Phase-lead and Phase-lag Controllers
02:27Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...